| Manal Omar, | |
|
6245 Inkster Rd, Garden City, MI 48135-4001 | |
| (734) 458-4486 | |
| Not Available |
| Full Name | Manal Omar |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 6245 Inkster Rd, Garden City, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093197121 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 5101021707 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Garden City Hospital | Garden city, MI | Hospital |
| Entity Name | Emergency Department Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225083595 PECOS PAC ID: 9436048998 Enrollment ID: O20040312000466 |
News Archive
In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.
Roche Molecular Systems, Inc. announced today that the U.S. Food & Drug Administration (FDA) cleared its new LightCycler® MRSA Advanced Test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) for clinical use in the United States.
In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,759,304, entitled "Targeting Complement Factor H For Treatment of Diseases", covering the composition of matter for its lead product candidate, TT30, a novel fusion protein that selectively binds to complement activated cells to locally regulate the complement system.
› Verified 8 days ago
| Entity Name | Observation Emergency Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497920524 PECOS PAC ID: 9133292410 Enrollment ID: O20080719000024 |
News Archive
In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.
Roche Molecular Systems, Inc. announced today that the U.S. Food & Drug Administration (FDA) cleared its new LightCycler® MRSA Advanced Test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) for clinical use in the United States.
In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,759,304, entitled "Targeting Complement Factor H For Treatment of Diseases", covering the composition of matter for its lead product candidate, TT30, a novel fusion protein that selectively binds to complement activated cells to locally regulate the complement system.
› Verified 8 days ago
| Entity Name | Michigan Staffing Solutions, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952889651 PECOS PAC ID: 9537413067 Enrollment ID: O20190109001351 |
News Archive
In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.
Roche Molecular Systems, Inc. announced today that the U.S. Food & Drug Administration (FDA) cleared its new LightCycler® MRSA Advanced Test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) for clinical use in the United States.
In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,759,304, entitled "Targeting Complement Factor H For Treatment of Diseases", covering the composition of matter for its lead product candidate, TT30, a novel fusion protein that selectively binds to complement activated cells to locally regulate the complement system.
› Verified 8 days ago
| Entity Name | Myna |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396351037 PECOS PAC ID: 6406257310 Enrollment ID: O20210630000232 |
News Archive
In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.
Roche Molecular Systems, Inc. announced today that the U.S. Food & Drug Administration (FDA) cleared its new LightCycler® MRSA Advanced Test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) for clinical use in the United States.
In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,759,304, entitled "Targeting Complement Factor H For Treatment of Diseases", covering the composition of matter for its lead product candidate, TT30, a novel fusion protein that selectively binds to complement activated cells to locally regulate the complement system.
› Verified 8 days ago
| Entity Name | Ihp Mi Emergency Medicine Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861147456 PECOS PAC ID: 2365821634 Enrollment ID: O20220616000277 |
News Archive
In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.
Roche Molecular Systems, Inc. announced today that the U.S. Food & Drug Administration (FDA) cleared its new LightCycler® MRSA Advanced Test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) for clinical use in the United States.
In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,759,304, entitled "Targeting Complement Factor H For Treatment of Diseases", covering the composition of matter for its lead product candidate, TT30, a novel fusion protein that selectively binds to complement activated cells to locally regulate the complement system.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Manal Omar, 44701 Fenwick Dr, Canton, MI 48188-3245 Ph: () - | Manal Omar, 6245 Inkster Rd, Garden City, MI 48135-4001 Ph: (734) 458-4486 |
News Archive
In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.
Roche Molecular Systems, Inc. announced today that the U.S. Food & Drug Administration (FDA) cleared its new LightCycler® MRSA Advanced Test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) for clinical use in the United States.
In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,759,304, entitled "Targeting Complement Factor H For Treatment of Diseases", covering the composition of matter for its lead product candidate, TT30, a novel fusion protein that selectively binds to complement activated cells to locally regulate the complement system.
› Verified 8 days ago
John Swan, D.O Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-8448 | |
Damanjeet Singh Sahi, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486 | |
Mrs. Allie Lee Cherfan, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-421-3300 | |
Dina Alaa Elbanna, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486 | |
Dr. Kevin James Macconnachie, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486 | |
Dr. Kaitlin Mcdonald, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-421-3300 |